Top

Published in:

Open Access 01-12-2023 | Breast Cancer | Research

Valproic acid inhibits cell growth in both MCF-7 and MDA-MB231 cells by triggering different responses in a cell type-specific manner

Authors: Francesca Giordano, Alessandro Paolì, Martina Forastiero, Stefania Marsico, Francesca De Amicis, Mariangela Marrelli, Giuseppina Daniela Naimo, Loredana Mauro, Maria Luisa Panno

Published in: Journal of Translational Medicine | Issue 1/2023

Abstract

Background

Breast cancer is the second leading cause of death among women after lung cancer. Despite the improvement in prevention and in therapy, breast cancer still remains a threat, both for pre- and postmenopausal women, due to the development of drug resistance. To counteract that, novel agents regulating gene expression have been studied in both hematologic and solid tumors. The Histone Deacetylase (HDAC) inhibitor Valproic Acid (VA), used for epilepsy and other neuropsychiatric diseases, has been demonstrated a strong antitumoral and cytostatic activity. In this study, we tested the effects of Valproic Acid on the signaling pathways involved in breast cancer cells viability, apoptosis and in Reactive Oxygen Species (ROS) production using ER-α positive MCF-7 and triple negative MDA-MB-231 cells.

Methods

Cell proliferation assay was performed by MTT Cell cycle, ROS levels and apoptosis were analyzed by flow cytometry, protein levels were detected by Western Blotting.

Results

Cell treatment with Valproic Acid reduced cell proliferation and induced G0/G1 cell cycle arrest in MCF-7 and G2/M block in MDA-MB-231 cells. In addition, in both cells the drug enhanced the generation of ROS by the mitochondria. In MCF-7 treated cells, it has been observed a reduction in mitochondrial membrane potential, a down regulation of the anti-apoptotic marker Bcl-2 and an increase of Bax and Bad, leading to release of cytochrome C and PARP cleavage. Less consistent effects are recorded in MDA-MB-231 cells, in which the greater production of ROS, compared to MCF-7cells, involves an inflammatory response (activation of p-STAT3, increased levels of COX2).

Conclusions

Our results have demonstrated that in MCF-7 cells the Valproic Acid is a suitable drug to arrest cell growth, to address apoptosis and mitochondrial perturbations, all factors that are important in determining cell fate and health. In a triple negative MDA-MB 231 cells, valproate directs the cells towards the inflammatory response with a sustained expression of antioxidant enzymes. Overall, the not always unequivocal data between the two cellular phenotypes indicate that further studies are needed to better define the use of the drug, also in combination with other chemotherapy, in the treatment of breast tumors.

Available only for authorised users

Suvà ML, Riggi N, Bernstein BE. Epigenetic reprogramming in cancer. Science. 2013;339(6127):1567–70. https://doi.org/10.1126/science.1230184.CrossRefPubMed

Bao X, Anastasov N, Rosemann WY. novel epigenetic signature for overall survival prediction in patients with breast cancer. J Transl Med. 2019;17:380. https://doi.org/10.1186/s12967-019-2126-6.CrossRefPubMedPubMedCentral

Yang XJ, Seto E. HATs and HDACs: from structure, function and regulation to novel strategies for therapy and prevention. Oncogene. 2007;26(37):5310–8. https://doi.org/10.1038/sj.onc.1210599.CrossRefPubMed

Minamiya Y, Ono T, Saito H, Takahashi N, Ito M, Mitsui M, Motoyama S, Ogawa J. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer. 2011;74(2):300–4. https://doi.org/10.1016/j.lungcan.2011.02.019.CrossRefPubMed

Hsieh CL, Ma HP, Su CM, Chang YJ, Hung WY, Ho YS, Huang WJ, Lin RK. Alterations in histone deacetylase 8 lead to cell migration and poor prognosis in breast cancer. Life Sci. 2016;151:7–14. https://doi.org/10.1016/j.lfs.2016.02.092.CrossRefPubMed

Bennett RL, Licht JD. Targeting epigenetics in cancer. Annu Rev Pharmacol Toxicol. 2018. https://doi.org/10.1146/annurevpharmtox-010716-105106.CrossRefPubMed

Krusche CA, Wulfing P, Kersting C, Vloet A, Bocker W, Kiesel L, Beier HM, Alfer J. Histone deacetylase-1 and—3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat. 2005;90:15–23. https://doi.org/10.1007/s10549-004-1668-2.CrossRefPubMed

Muller BM, Jana L, Kasajima A, Lehmann A, Prinzler J, Budczies J, Winzer KJ, Dietel M, Weichert W, Denkert C. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer–overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer. 2013;13:215. https://doi.org/10.1186/1471-2407-13-215.CrossRefPubMedPubMedCentral

Seo J, Min SK, Park HR, Kim DH, Kwon MJ, Kim LS, Ju YS. Expression of Histone Deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in Invasive Ductal Carcinomas of the Breast. J Breast Cancer. 2014;17:323–31. https://doi.org/10.4048/jbc.2014.17.4.323.CrossRefPubMedPubMedCentral

10.

Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, Bowcock AM, Harbour JW. Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res. 2012;18(2):408–16. https://doi.org/10.1158/1078-0432.CCR-11-0946.CrossRefPubMed

11.

Tate CR, Rhodes LV, Segar HC, Driver JL, Pounder FN, Burow ME, Collins-Burow BM. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res. 2012;14(3):R79. https://doi.org/10.1186/bcr3192.CrossRefPubMedPubMedCentral

12.

Ellis L, Ku SY, Ramakrishnan S, Lasorsa E, Azabdaftari G, Godoy A, Pili R. Combinatorial antitumor effect of HDAC and the PI3K-Akt-mTOR pathway inhibition in a pten defecient model of prostate cancer. Oncotarget. 2013;4(12):2225–36. https://doi.org/10.18632/oncotarget.1314.CrossRefPubMedPubMedCentral

13.

Bao L, Diao H, Dong N, Su X, Wang B, Mo Q, Yu H, Wang X, Chen C. Histone deacetylase inhibitor induces cell apoptosis and cycle arrest in lung cancer cells via mitochondrial injury and p53 up-acetylation. Cell Biol Toxicol. 2016. https://doi.org/10.1007/s10565-016.CrossRefPubMedPubMedCentral

14.

Jovanovic J, Ronneberg JA, Tost J, Kristensen V. The epigenetics of breast cancer. Mol Oncol. 2010. https://doi.org/10.1016/j.molonc.2010.04.002.CrossRefPubMedPubMedCentral

15.

Meyyappan M, Wong H, Hull C, Riabowol KT. Increased expression of cyclin D2 during multiple states of growth arrest in primary and established cells. Mol Cell Biol. 1998;18:3163–72. https://doi.org/10.1128/MCB.18.6.3163.CrossRefPubMedPubMedCentral

16.

Evron E, Umbricht CB, Korz D, Raman V, Loeb DM, Niranjan B, Buluwela L, Weitzman SA, Marks J, Sukumar S. Loss of cyclin D2 expression in the majority of breast cancers is associated with promoter hypermethylation. Cancer Res. 2001;61:2782–7.PubMed

17.

Wagner JM, Hackanson B, Lübbert M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy epigenetics. Clin. 2010. https://doi.org/10.1007/s13148-010-0012-4.CrossRef

18.

Chateauvieux S, Morceau F, Dicato M, Diederich M. Molecular and therapeutic potential and toxicity of valproic acid. J Biomed Biotechnol. 2010. https://doi.org/10.1155/2010/479364.CrossRefPubMedPubMedCentral

19.

Cincarova L, Zdrahal Z, Fajkus J. New perspectives of valproic acid in clinical practice. Expert Opin Investig Drugs. 2013;22:1535–47. https://doi.org/10.1517/13543784.2013.853037.CrossRefPubMed

20.

Tinari N, De Tursi M, Grassadonia A, Zilli M, Stuppia L, Iacobelli S, Natoli C. An epigenetic approach to pancreatic cancer treatment: the prospective role of histone deacetylase inhibitors. Curr Cancer Drug Targets. 2012;12:439–52. https://doi.org/10.2174/156800912800190884.CrossRefPubMed

21.

Giordano F, Naimo GD, Nigro A, Romeo F, Paolì A, De Amicis F, Vivacqua A, Morelli C, Mauro L, Panno ML. Valproic acid addresses neuroendocrine differentiation of LNCaP cells and maintains cell survival. Drug Des Devel Ther. 2019;2019(13):4265–74. https://doi.org/10.2147/DDDT.S229930.eCollection.CrossRef

22.

Chelluri R, Caza T, Woodford MR, Reeder JE, Bratslavsky G, Byler T. Valproic acid alters angiogenic and trophic gene expression in human prostate cancer models. Anticancer Res. 2016;36:5079–86. https://doi.org/10.21873/anticanres.11077.CrossRefPubMed

23.

Siegel RL, Miller KD, Jemal A. Cancer statistics. Cancer J Clin. 2018;68:7–30. https://doi.org/10.3322/caac.21442.CrossRef

24.

Soldi R, Cohen AL, Cheng L, Sun Y, Moos PJ, Bild AH. A genomic approach to predict synergistic combinations for breast cancer treatment. Pharmacogenomics J. 2013;13(1):94–104. https://doi.org/10.1038/tpj.2011.48.CrossRefPubMed

25.

De Marchi T, Foekens JA, Umar A, Martens JW. Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer. Drug Discov Today. 2016;21(7):1181–8. https://doi.org/10.1016/j.drudis.2016.05.012.CrossRefPubMed

26.

Harrelson JP, Lee MW. Expanding the view of breast cancer metabolism: promising molecular targets and therapeutic opportunities. Pharmacol Ther. 2016;167:60–73. https://doi.org/10.1016/j.pharmthera.2016.07.014.CrossRefPubMed

27.

Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol. 2007;1:19–25. https://doi.org/10.1016/j.molonc.2007.01.001.CrossRefPubMedPubMedCentral

28.

Wawruszak A, Luszczki JJ, Kalafut J, Okla K, Halasa M, Rivero-Muller A, Stepulak A. Additive pharmacological interaction between cisplatin (CDDP) and histone deacetylase inhibitors (HDIs) in MDA-MB-231 Triple negative breast cancer (TNBC) cells with altered notch1 activity-an isobolographic analysis. Int J Mol Sci. 2019;20(15):3663. https://doi.org/10.3390/ijms20153663.CrossRefPubMedPubMedCentral

29.

Scordamaglia D, Cirillo F, Talia M, Santolla MF, Rigiracciolo DC, Muglia L, Zicarelli A, De Rosis S, Giordano F, Miglietta AM, De Francesco EM, Vella V, Belfiore A, Lappano R, Maggiolini M. Metformin counteracts stimulatory effects induced by insulin in primary breast cancer cells. J Transl Med. 2022;20:263. https://doi.org/10.1186/s12967-022-03463-y.CrossRefPubMedPubMedCentral

30.

Nigro A, Frattaruolo L, Fava M, De Napoli I, Greco M, Comande A, De Santo M, Pellegrino M, Ricci E, Giordano F, Perrotta I, Leggio A, Pasqua L, Sisci D, Cappello AR, Morelli C. Bortezomib-loaded mesoporous silica nanoparticles selectively alter metabolism and induce death in multiple myeloma cells. Cancers. 2020;12(9):2709. https://doi.org/10.3390/cancers12092709.CrossRefPubMedPubMedCentral

31.

Eidet JR, Pasovic L, Maria R, Jackson CJ, Utheim TP. Objective assessment of changes in nuclear morphology and cell distribution following induction of apoptosis. Diagn Pathol. 2014;12(9):92. https://doi.org/10.1186/1746-1596-9-92.CrossRef

32.

Pietkiewicz S, Schmidt JH, Lavrik IN. Quantification of apoptosis and necroptosis at the single cell level by a combination of Imaging Flow cytometry with classical annexin v/propidium iodide staining. J Immunol Methods. 2015;423:99–103. https://doi.org/10.1016/j.jim.2015.04.025.CrossRefPubMed

33.

Dworkin AM, Huang TH, Toland AE. Epigenetic alterations in the breast:implications for breast cancer detection, prognosis and treatment. Semin Cancer Biol. 2009;19:165–71. https://doi.org/10.1016/j.semcancer.2009.02.007.CrossRefPubMedPubMedCentral

34.

Shin E, Lee Y, Koo JS. Differential expression of the epigenetic methylation-related protein DNMT1 by breast cancer molecular subtype and stromal histology. J Transl Med. 2016;14:87. https://doi.org/10.1186/s12967-016-0840-x.CrossRefPubMedPubMedCentral

35.

Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74. https://doi.org/10.1016/j.cell.2011.02.013.CrossRefPubMed

36.

Pucci B, Kasten M, Giordano A. Cell cycle and apoptosis. Neoplasia. 2000;2:291–9. https://doi.org/10.1038/sj.neo.7900101.CrossRefPubMedPubMedCentral

37.

Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res. 1998;58:5315–20.PubMed

38.

Hirohashi Y, Torigoe T, Maeda A, et al. An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin. Clin Cancer Res. 2002;8:1731–9.PubMed

39.

Kennedy SM, O’Driscoll L, Purcell R, et al. Prognostic importance of survivin in breast. Cancer. 2003;88:1077–83. https://doi.org/10.1038/sj.bjc.6600776.CrossRef

40.

Miller M, Smith D, Windsor A, Kessling A. Survivin gene expression and prognosis in recurrent colorectal cancer. Gut. 2001;48:137–8. https://doi.org/10.1136/gut.48.1.137.CrossRefPubMedPubMedCentral

41.

Adida C, Haioun C, Gaulard P, et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood. 2000;96:1921–5.PubMed

42.

Asanuma H, Torigoe T, Kamiguchi K, et al. Survivin expression is regulated by coexpression of human epidermal growth factor receptor 2 and epidermal growth factor receptor via phosphatidylinositol 3-kinase/AKT signaling pathway in breast cancer cells. Cancer Res. 2005;65:11018–25. https://doi.org/10.1158/0008-5472.CAN-05-0491.CrossRefPubMed

43.

Sabbatino F, Conti V, Liguori L, Polcaro G, Corbi G, Manzo V, Tortora V, Carlomagno C, Vecchione C, Filippelli A, Pepe S. Molecules and mechanisms to overcome oxidative stress inducing cardiovascular disease in cancer patients. Life. 2021;11(2):105. https://doi.org/10.3390/life11020105.CrossRefPubMedPubMedCentral

44.

Wawruszak A, Halasa M, Okon E, Kukula-Koch W, Stepulak A. Valproic acid and breast cancer: state of the art in 2021. Cancers. 2021;13:3409. https://doi.org/10.3390/cancers13143409.CrossRefPubMedPubMedCentral

45.

Nazlıhan A, Merve E, Elif E, Ul E, AsumanHatice T, Ferda A. Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells. Chem Biol Interact. 2018;280:51–8. https://doi.org/10.1016/j.cbi.2017.12.003.CrossRef

46.

Thornton TM, Rincon M. Non-classical p38 map kinase functions: cell cycle checkpoints and survival. Int J Biol Sci. 2009;5:44. https://doi.org/10.7150/ijbs.5.44.CrossRefPubMed

47.

Martínez-Limón A, Joaquin M, Caballero M, Posas F, de Nadal E. The p38 pathway: from biology to cancer therapy. Int J Mol Sci. 2020;21(6):1913. https://doi.org/10.3390/ijms21061913.CrossRefPubMedPubMedCentral

48.

Low HB, Zhang Y. Regulatory roles of MAPK phosphatases in cancer. Immune Netw. 2016;16:85–98. https://doi.org/10.4110/in.2016.16.2.85.CrossRefPubMedPubMedCentral

49.

Cellurale C, Girnius N, Jiang F, Cavanagh-Kyros J, Lu S, Garlick DS, Mercurio AM, Davis RJ. Role of JNK in mammary gland development and breast cancer. Cancer Res. 2012;72:472–81. https://doi.org/10.1158/0008-5472.CAN-11-1628.CrossRefPubMed

50.

Girnius N, Edwards YJ, Garlick DS, Davis RJ. The cJUN NH2-terminal kinase (JNK) signaling pathway promotes genome stability and prevents tumor initiation. Elife. 2018;7:e36389. https://doi.org/10.7554/eLife.36389.CrossRefPubMedPubMedCentral

51.

Li W, Xu M, Li Y, Huang Z, Zhou J, Zhao Q, Le K, Dong F, Wan C, Yi P. Comprehensive analysis of the association between tumor glycolysis and immune/inflammation function in breast cancer. J Transl Med. 2020;18:92. https://doi.org/10.1186/s12967-020-02267-2.CrossRefPubMedPubMedCentral

52.

Qiu L, Ma Y, Chen X, Zhou L, Zhang H, Zhong G, Zhang L, Tang J. Heparin-binding growth factor (HDGF) drives radioresistance in breast cancer by activating the STAT3 signaling pathway. J Transl Med. 2021;19:344. https://doi.org/10.1186/s12967-021-03021-y.CrossRefPubMedPubMedCentral

53.

Perillo B, Di Donato M, Pezone A, Di Zazzo E, Giovannelli P, Galasso G, Castoria G, Migliaccio A. ROS in cancer therapy: the bright side of the moon. Exp Mol Med. 2020;52:192–203. https://doi.org/10.1038/s12276-020-0384-2.CrossRefPubMedPubMedCentral

54.

Xi W, Guo W, Wu S, Wang L, Huang P, Liu J, Fang B. Oxidative stress in NSC-741909—induced apoptosis of cancer cells. J Transl Med. 2010;8:37.CrossRef

55.

Renschler MF. The emerging role of reactive oxygen species in cancer therapy. Eur J Cancer. 2004;40:1934–40. https://doi.org/10.1016/j.ejca.2004.02.031.CrossRefPubMed

56.

Kotamraju S, Chitambar CR, Kalivendi SV, Joseph J, Kalyanaraman B. Transferrin receptor-dependent iron uptake is responsible for doxorubicinmediated apoptosis in endothelial cells: role of oxidant-induced iron signaling in apoptosis. J Biol Chem. 2002;277:17179–87. https://doi.org/10.1074/jbc.M111604200.CrossRefPubMed

57.

Yi J, Gao F, Shi G, Li H, Wang Z, Shi X, Tang X. The inherent cellular level of reactive oxygen species: one of the mechanisms determining the apoptotic susceptibility of leukemic cells to arsenic trioxide. Apoptosis. 2002;7:209–15. https://doi.org/10.1023/a:1015331229263.CrossRefPubMed

58.

Fortunati N, Bertino S, Costantino L, Bosco O, Vercellinatto I, Catalano MG, Boccuzzi G. Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells. Cancer Lett. 2008;259(2):156–64. https://doi.org/10.1016/j.canlet.2007.10.006.CrossRefPubMed

59.

Zhou X, Zhen L, Xuanyu W, Ge J, Changliang S, Shuangping L. Metabolomics reveals the effect of valproic acid on MCF-7 and MDA-MB-231 cells. Xenobiotica. 2020;50(3):252–60. https://doi.org/10.1080/00498254.2019.1618510.CrossRefPubMed

Title: Valproic acid inhibits cell growth in both MCF-7 and MDA-MB231 cells by triggering different responses in a cell type-specific manner
Authors: Francesca Giordano
Alessandro Paolì
Martina Forastiero
Stefania Marsico
Francesca De Amicis
Mariangela Marrelli
Giuseppina Daniela Naimo
Loredana Mauro
Maria Luisa Panno
Publication date: 01-12-2023
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Valproate
Published in: Journal of Translational Medicine / Issue 1/2023
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/s12967-023-04015-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Association of diabetes risk reduction diet with renal cancer risk in 101,755 participants: a prospective study

Unfolded protein response pathways in stroke patients: a comprehensive landscape assessed through machine learning algorithms and experimental verification

Cellular senescence in the response of HR+ breast cancer to radiotherapy and CDK4/6 inhibitors

Identification of transcription factors related to diabetic tubulointerstitial injury

Spermatogenesis associated serine rich 2 like plays a prognostic factor and therapeutic target in acute myeloid leukemia by regulating the JAK2/STAT3/STAT5 axis

Identification of memory B-cell-associated miRNA signature to establish a prognostic model in gastric adenocarcinoma

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials